Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report.

ABSTRACT:

Background

Fibroblast growth factor receptor-2 (FGFR-2) mutations are frequently observed in intrahepatic cholangiocarcinoma (ICC). While FGFR2-targeted therapies are primarily studied in advanced ICC, this report presents a rare case of locally recurrent ICC treated with systemic therapy, leading to significant tumor regression and successful R0 resection.

Case presentation

A 51-year-old female underwent right posterior hepatectomy and cholecystectomy in 2018 for ICC. In August 2022, postoperative MRI revealed tumor recurrence near the hepatic vein, accompanied by intrahepatic bile duct dilation and a tumor thrombus. Given the tumor's proximity to critical structures and confirmed FGFR-2 fusion, systemic therapy with pemigatinib and sintilimab was initiated. After four cycl

SUBMITTER: Yang Y 

PROVIDER: S-EPMC12006668 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature